EVIDENCE LIBRARY
Obese ICU Patients and Midazolam: Why Surgical Pharmacokinetic Data Need Caution
A critical-care review highlights the evidence gap between small obesity pharmacokinetic studies and dosing decisions in unstable ICU patients.
A critical-care review highlights the evidence gap between small obesity pharmacokinetic studies and dosing decisions in unstable ICU patients.
Where the evidence came from
The authors describe a literature base often involving small samples, single doses, healthy volunteers, or non-ICU surgical patients. For midazolam, studies suggested greater distribution volume without proportionately greater clearance. That distinction raises separate questions about initial distribution and accumulation during continuing treatment.
What extrapolation leaves unresolved
Critical illness introduces changing organ function, co-medication, and physiological instability. The review therefore offers a reasoned dosing framework rather than a regimen proven by adequately powered ICU outcome trials in extreme obesity. A conclusion about an individual infusion should consider duration, titration, response, and clearance-related illness alongside the body-weight calculation. Neither a surgical pharmacokinetic estimate nor a weight category can reconstruct that patient’s course by itself. The paper’s contribution is explaining how limited evidence informs judgment while leaving important uncertainties about outcomes and optimal dosing.
Source paper
Original analysis of the supplied journal article, identified as PMC7282067.